Racivir
| |
Clinical data | |
---|---|
Routes of administration | Investigational |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
NIAID ChemDB | |
Chemical and physical data | |
Formula | C8H10FN3O3S |
Molar mass | 247.25 g/mol |
3D model (JSmol) | |
| |
|
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomer of emtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.
References
- ↑ "Racivir". AIDSmeds.com. March 24, 2006. Archived from the original on 2014-01-02. Retrieved March 21, 2008.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.